Xtalks — The Life Science Community™, Online webinar
2026-09-17
The rapid growth of GLP-1 receptor agonists, dual agonists and other emerging therapies is accelerating drug development across obesity and type 2 diabetes. At the same time, sponsors face increasing pressure to demonstrate more than just weight loss or glycemic control. This webinar will explore how phase-appropriate endpoint strategies can support stronger development decisions and more differentiated evidence across obesity clinical trials. Development teams increasingly need to understand how a therapy affects the whole patient, including symptoms, treatment experience, glucose patterns, body composition, organ health and cardiovascular safety. However, the questions sponsors need to confidently answer in early-phase trials differ from those addressed in larger Phase II and Phase III programs. Join the featured experts in eCOA, cardiac safety and medical imaging to learn how phase-appropriate endpoint solutions that generate high-quality, informative data can support critical decisions. From detecting early safety and efficacy signals informing dose selection, go/no-go and study design decisions, to characterizing treatment benefit and risk building a differentiated, regulator-ready evidence package, implementing the right endpoint strategy and technologies is paramount. Register to learn how an integrated, phase-appropriate endpoint strategy can help teams identify meaningful signals earlier, reduce development uncertainty and generate stronger evidence for regulatory review and product differentiation.
|
|
|
Invited Speakers:
|
|
Todd Rudo, MD, EVP, Chief Medical Officer, Clario Vic Patel, MD, PhD, VP, Chief Medical Officer, Cardiology, Clario Brian K. Rundle, PhD, Scientific Advisor, Clario Mark W. Tengowski, DVM, MS, PhD, Director, Medical & Scientific Affairs, Medical Imaging, Clario
|
|